Product Description
Progressed ATTC drug candidate with plans for global IND filings and clinical trial initiations in 2026. (Sourced from: https://www.benzinga.com/pressreleases/26/03/g51060341/hutchmed-reports-2025-full-year-results-and-business-updates)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: Hutchmed
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07718581 |
2026-830-GLOB1 | P2 |
Not yet recruiting |
Oncology Solid Tumor Unspecified |
2028-06-26 |
61% |
2026-07-23 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|